$ImmunityBio (IBRX.US)$Buy below 7.5 and don't sell; if the closing price stays above 7.5, a short squeeze will occur, and we'll see $10 next week 😂

$ImmunityBio (IBRX.US)$ Reminder – Yesterday's FDA news is relevant. Here’s why.
Non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) unresponsive to BCG accounts for only about 10% of (BCG-unresponsive) disease, while the less aggressive papillary type makes up the remaining 90%.
Therefore, if the FDA approves ANKTIVA for papillary treatment, TAM demand will increase ninefold. We are still only talking about bladder cancer.
Now, ImmunityBio believes it has found a path forward with the latest update. In fact, the company stated on Tuesday that the FDA recommended the company provide 'additional information' to support the resubmission of the sBLA.
ImmunityBio added that this does 'not involve initiating or designing any new clinical trials.' The company plans to submit the new information to the agency within the next 30 days.
The team highlighted the long-term outcomes of Quilt-3.032 recently published in The Journal of Urology. These showed that Anktiva plus BCG achieved 12-month DFS and PFS rates of 58% and 95%, respectively, with 92% of patients avoiding cystectomy (bladder removal surgery) within one year.
ImmunityBio described these results as 'unprecedented.'

$ImmunityBio (IBRX.US)$This is a summary of a professional press release in the biotechnology and healthcare field. The following is its Traditional Chinese translation:
Translation content
ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA). The meeting discussed the company’s submitted supplemental Biologics License Application (sBLA) for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC) patients with papillary tumors who are unresponsive to BCG.
ImmunityBio provided an overview of the clinical status of its papillary disease program, including more than five years of follow-up data supporting the indication for papillary tumors. Key highlights are summarized below:
* Disease-Specific Survival (DSS): Approximately 96% at 36 months, with the median survival not yet reached even after five years of follow-up.
* Cystectomy-Free Rate: The one-year and three-year cystectomy avoidance rates were as high as 92% and 82%, respectively.
* Safety: The safety profile was consistent with the currently approved indication for 'Carcinoma In Situ (CIS) with or without papillary tumors'...

$ImmunityBio (IBRX.US)$ The European market has reached €6.24 and $7.20.

$ImmunityBio (IBRX.US)$ The leading force in cancer innovation is making real progress. Dr. Patrick Soon-Shiong and ImmunityBio are advancing Anktiva, a groundbreaking IL-15 superagonist immunotherapy that activates and proliferates the body's natural killer (NK) cells and memory T cells to precisely target and destroy tumors.
Instead of using harsh chemotherapy that harms healthy cells and weakens immunity, Anktiva restores and strengthens the immune system for targeted, longer-lasting attacks, offering hope for fewer side effects and better outcomes.
The visionary behind it, @DrPatrick, a surgeon, inventor, and the founder, executive chairman, and global chief scientific officer of ImmunityBio.
Anktiva received FDA approval in 2024 for BCG-unresponsive non-muscle invasive #bladder cancer (NMIBC) with carcinoma in situ. In January 2026, the Saudi FDA granted accelerated approval for:
• Anktiva + checkpoint inhibitor in metastatic non-small cell #lungcancer (the world's first subcutaneous IL-15 treatment!)
• #Anktiva + BCG in BCG
unresponsive NMIBC
In addition, strong trial data shows immune restoration and extended survival times in difficult cases...

$ImmunityBio (IBRX.US)$ This passage comes from Dr. Patrick Soon-Shiong, the founder and executive chairman of ImmunityBio (stock code: IBRX). He is describing the company's latest 'Global Strategic Blueprint,' which focuses on leveraging the body's own immune system to revolutionize cancer treatment.
Below is a detailed interpretation of the 'blueprint' he mentioned.
1. Core Vision: Cancer BioShield™
This is a grand concept proposed by Dr. Huang. He believes that cancer treatment should not only focus on 'killing tumors' but also emphasize 'protecting the immune system.'
* Combating Lymphopenia: Traditional chemotherapy and radiotherapy destroy cancer cells while also wiping out immune cells (lymphocytes). Dr. Huang refers to this as 'immune system collapse.'
* Repair and Activation: The goal of the Cancer BioShield platform is to restore and enhance the patient’s immunity through its core drug Anktiva, acting like a 'shield' so that the body can continuously monitor and eliminate cancer cells, preventing recurrence.
2. Key Technologies and Drugs
* Anktiva (N-803): This is currently the company's flagship product. It is an IL-15 superagonist capable of potently activating natural killer cells (NK) and T cells...

$ImmunityBio (IBRX.US)$ Dr. Shiong, how high do you want to drive the stock price???

$ImmunityBio (IBRX.US)$ The anticipated positive news is expected to arrive soon, with the FDA granting rapid approval!